Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 +38.60%57 PB Ratio is 2.56 as of Jul. 15, 2026, which is 4% above its 10-year median of 2.47. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Medrx Co ranks better than 52.06% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Medrx Co's share price is 円79.00. Medrx Co's Book Value per Share for the quarter that ended in Dec. 2025 was 円30.86. Hence, Medrx Co's PB Ratio of today is 2.56.
The historical rank and industry rank for Medrx Co's PB Ratio or its related term are showing as below:
TSE:4586'
s PB Ratio Range Over the Past 10 Years
Min: 1.13 Med: 2.47 Max: 8.65
Current: 2.55
During the past 13 years, Medrx Co's highest PB Ratio was 8.65. The lowest was 1.13. And the median was 2.47.
TSE:4586's PB Ratio is ranked better than 52.06% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs TSE:4586: 2.55
During the past 12 months, Medrx Co's average Book Value Per Share Growth Rate was -24.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -18.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -22.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Medrx Co was 62.00% per year. The lowest was -32.60% per year. And the median was -21.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medrx Co PB Ratio Related Terms
Medrx Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Medrx Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medrx Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Medrx Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medrx Co (TSE:4586) has a PB Ratio of 2.56 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medrx Co and its competitors. This is near median its historical median of 2.47. Over the past decade, Medrx Co's PB Ratio has ranged from 1.13 to 8.65. According to the industry distribution chart, Medrx Co ranks #442 out of 922 companies in the Drug Manufacturers industry, placing it in the top 47.9%.
Is Medrx Co's PB Ratio too high?
Medrx Co's current PB Ratio of 2.56 is near median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 8.65. The Drug Manufacturers industry median PB Ratio is 1.92. Medrx Co's value of 2.56 is 33.3% above this industry median. Based on the distribution chart, Medrx Co ranks #442 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #442 out of 922 companies for PB Ratio. This puts Medrx Co in the upper half of its industry. The industry median PB Ratio is 1.92. Medrx Co's value of 2.56 is 33.3% above this benchmark. Historically, Medrx Co's own PB Ratio has ranged from 1.13 to 8.65 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 1.92, Medrx Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medrx Co's current PB Ratio of 2.56 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medrx Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current PB Ratio is 2.56, which is near median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円79.00 — trading 12% above its estimated fair value. The current PB Ratio is 2.56, which is near median its 10-year median of 2.47 and 33.3% above the Drug Manufacturers industry median of 1.92. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current PB Ratio is 2.56 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be overvalued.
The current stock price of 円79.00 is trading 12% above its estimated GF Value™ of 円70.55.
GuruFocus considers Medrx Co to be Modestly Undervalued.
Key valuation signals for TSE:4586:
PB Ratio: 2.56 (near median its 10-year median of 2.47)
GF Value™: 円70.55 vs. price of 円79.00 (12% above fair value)
Industry Position: 33.3% above the Drug Manufacturers median (#442 of 922)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score
Get the complete analysis for TSE:4586
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
